Asset Details
Do you wish to reserve the book?
Adjuvant Docetaxel for Node-Positive Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adjuvant Docetaxel for Node-Positive Breast Cancer
Do you wish to request the book?
Adjuvant Docetaxel for Node-Positive Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adjuvant Docetaxel for Node-Positive Breast Cancer
2005
Overview
This randomized trial included almost 1500 women with breast cancer and positive axillary nodes and compared treatment with doxorubicin and cyclophosphamide combined with either fluorouracil or docetaxel. The rates of disease-free and overall survival were significantly higher among women in the docetaxel group.
This trial compared treatment with doxorubicin and cyclophosphamide combined with either fluorouracil or docetaxel. The rates of disease-free and overall survival were significantly higher among women in the docetaxel group.
Adjuvant chemotherapy for breast cancer has undergone a major change over the past two decades. Chemotherapy with a regimen that includes an anthracycline or a combination of cyclophosphamide, methotrexate, and fluorouracil significantly decreases the risks of disease recurrence and death among women with early-stage breast cancer.
1
The overview analysis of the Early Breast Cancer Trialists' Collaborative Group demonstrated that, as compared with standard treatment with cyclophosphamide, methotrexate, and fluorouracil, regimens that contained doxorubicin or epirubicin reduced the annual risk of recurrence of breast cancer by 12 percent and the annual risk of death by 11 percent. Rates of disease-free and . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Agents, Phytogenic - adverse effects
/ Antineoplastic Agents, Phytogenic - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - mortality
/ Cyclophosphamide - administration & dosage
/ Cyclophosphamide - adverse effects
/ Doxorubicin - administration & dosage
/ Doxorubicin - adverse effects
/ Female
/ Fluorouracil - administration & dosage
/ Fluorouracil - adverse effects
/ Humans
